Mechanism of accommodation in a sensitized human leukocyte antigen transgenic murine cardiac transplant model

Transplantation

Volumn 93, Issue 4, 2012, Pages 364-372

  Fukami, Naohiko ^a   Ramachandran, Sabarinathan ^a   Narayanan, Kishore ^a   Liu, Wei ^a   Nath, Dilip S ^a   Jendrisak, Martin ^a   Chapman, William ^a   Mohanakumar, Thalachallour ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Accommodation; Cardiac transplant; HLA antibodies; Mechanisms of rejection; Signal pathways

Indexed keywords

CHEMOKINE; COMPLEMENT COMPONENT C4; HEME OXYGENASE 1; HLA A2 ANTIGEN; HLA ANTIGEN; HLA ANTIGEN CLASS 1; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEIN BCL 2; PROTEIN BCL X; PROTEIN MIG; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BCL 2 GENE; BCL XL GENE; CARDIAC GRAFT REJECTION; CONTROLLED STUDY; GENE; GENE EXPRESSION; GENE FUNCTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; HEME OXYGENASE 1 GENE; HLA MATCHING; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; TRANSGENIC MOUSE;

ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; HEME OXYGENASE-1; HLA ANTIGENS; HLA-A2 ANTIGEN; HUMANS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MODELS, ANIMAL; PROTO-ONCOGENE PROTEINS C-BCL-2; TIME FACTORS;

EID: 84863166586     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3182406a6b     Document Type: Article

References (30)

1. Tanabe K, Takahashi K, Sonda K, et al. Long-term results of ABOincompatible living kidney transplantation:Asingle-center experience. Transplantation 1998; 65: 224.
2. Alkhunaizi AM, de Mattos AM, Barry JM, et al. Renal transplantation across the ABO barrier using A2 kidneys. Transplantation 1999; 67: 1319.
3. Alexandre GP, De Bruyere M, Squifflet JP, et al. Human ABOincompatible living donor renal homografts. Neth J Med 1985; 28: 231.
4. Alexandre GP, Squifflet JP, De BruyèreM, et al. Present experiences in a series of 26 ABO-incompatible living donor renal allografts. Transplant Proc 1987; 19: 4538.
5. Colvin RB, Smith RN. Antibody-mediated organ-allograft rejection. Nat Rev Immunol 2005; 5: 807.
6. Kupin WL, Venkat KK, Hayashi H, et al. Removal of lymphocytotoxic antibodies by pretransplant immunoadsorption therapy in highly sensitized renal transplant recipients. Transplantation 1991; 51: 324.
7. Palmer A, Taube D, Welsh K, et al. Removal of anti-HLA antibodies by extracorporeal immunoadsorption to enable renal transplantation. Lancet 1989; 1: 10.
8. Reisaeter AV, Leivestad T, Albrechtsen D, et al. Pretransplant plasma exchange or immunoadsorption facilitates renal transplantation in immunized patients. Transplantation 1995; 60: 242.
9. Ross CN, Gaskin G, Gregor-Macgregor S, et al. Renal transplantation following immunoadsorption in highly sensitized recipients. Transplantation 1993; 55: 785.
10. Glotz D, Antoine C, Julia P, et al. Desensitization and subsequent kidney transplantation of patients using intravenous immunoglobulins (IVIg). Am J Transplant 2002; 2: 758.
11. Glotz D, Haymann JP, Sansonetti N, et al. Suppression of HLA-specific alloantibodies by high-dose intravenous immunoglobulins (IVIG). A potential tool for transplantation of immunized patients. Transplantation 1993. 56: 335.
12. Bach FH, Ferran C, Hechenleitner P, et al. Accommodation of vascularized xenografts: Expression of "protective genes" by donor endothelial cells in a host Th2 cytokine environment. Nat Med 1997; 3: 196.
13. Fischel RJ, Bolman RM III, Platt JL, et al. Removal of IgM antiendothelial antibodies results in prolonged cardiac xenograft survival. Transplant Proc 1990; 22: 1077.
14. Hasan R, Van den Bogaerde J, Forty J, et al. Xenograft adaptation is dependent on the presence of antispecies antibody, not prolonged residence in the recipient. Transplant Proc 1992; 24: 531.
15. Leventhal JR, Sakiyalak P, Witson J, et al. The synergistic effect of combined antibody and complement depletion on discordant cardiac xenograft survival in nonhuman primates. Transplantation 1994; 57: 974.
16. Narayanan K, JendrisakMD,Phelan DL, et al.HLAclass I antibody mediated accommodation of endothelial cells via the activation of P13K/cAMP dependent PKA pathway. Transplant Immunol 2006; 15: 187.
17. Narayanan K, Jaramillo A, Phelan DL, et al. Pre-exposure to subsaturating concentrations of HLA class I antibodies confers resistance to endothelial cells against antibody complement-mediated lysis by regulating Bad through the phosphatidylinositol 3-kinase/Akt pathway. Eur J Immunol 2004; 34: 2303.
18. Smith CR, Jaramillo A, Liu W, et al. CD4+ T cell recognition of a single discordant HLA-A2-transgenic molecule through the indirect antigen presentation pathway induces acute rejection of murine cardiac allografts. Transplantation 2001; 71: 1640.
19. Bharat A, Narayanan K, Street T, et al. Early posttransplant inflammation promotes the development of alloimmunity and chronic human lung allograft rejection. Transplantation 2007; 83: 150.
20. Semiletova NV, Shen XD, Baibakov B, et al. Inhibition of chronic rejection by antibody induced vascular accommodation in fully allogeneic heart allografts. Transplantation 2005; 80: 1535.
21. Salama AD, Delikouras A, Pusey CD, et al. Transplant accommodation in highly sensitized patients: A potential role for Bcl-xL and alloantibody. Am J Transplant 2001; 1: 260.
22. Williams JM, Holzknecht ZE, Plummer TB, et al. Acute vascular rejection and accommodation: Divergent outcomes of the humoral response to organ transplantation. Transplantation 2004; 78: 1471.
23. Cooper DK, Good AH, Koren E, et al. Identification of alpha-galactosyl and other carbohydrate epitopes that are bound by human anti-pig antibodies: Relevance to discordant xenografting in man. Transpl Immunol 1993; 1: 198.
24. Cooper DK, Ye Y, Niekrasz M, et al. Specific intravenous carbohydrate therapy. A new concept in inhibiting antibody-mediated rejection-Experience with ABO-incompatible cardiac allografting in the baboon. Transplantation 1993; 56: 769.
25. Soares MP, Lin Y, Sato K, et al. Accommodation. Immunol Today 1999; 20: 434.
26. Ferran C, Stroka DM, Badrichani AZ, et al. A20 inhibits NF-kappaB activation in endothelial cells without sensitizing to tumor necrosis factor-mediated apoptosis. Blood 1998; 91: 2249.
27. Koch CA, Khalpey ZI, Platt JL. Accommodation: Preventing injury in transplantation and disease. J Immunol 2004; 172: 5143.
28. Zhen-Wei X, Jian-Le S, Qi Q, et al. Heme oxygenase-1 improves the survival of discordant cardiac xenograft through its anti-inflammatory and anti-apoptotic effects. Pediatr Transplant 2007; 11: 850.
29. Soares MP, Lin Y, Anrather J, et al. Expression of heme oxygenase-1 can determine cardiac xenograft survival. Nat Med 1998; 4: 1073.
30. Wang N, Lee JM, Tobiasch E, et al. Induction of xenograft accommodation by modulation of elicited antibody responses1 2. Transplantation 2002; 74: 334.